Ayvat, PinarSahin, Aye SaideSoner, Burak Cem2024-02-232024-02-2320192146-23721309-9566https://doi.org/10.5222/buchd.2019.81084https://hdl.handle.net/20.500.12452/16829Objective: Parkinson's disease is one of the most frequently seen neurodegenerative disorders. A definite cure for this disease is not available yet. Agomelatin is the synthetic analog of melatonin hormone that is synthesized in, and released from the pineal gland . Agomelatin shows its antidepressant effects on central nervous system (CNS) by activating melatonin receptors MT1 and MT2 and antagonizing serotonin 5-HT2C receptors stimulated by monoamine transmitters. In this study, we examined the effects of oral agomelatin administration on Parkinson disease-induced experimental rats by using 6-OHDA. Methods: We administered unilateral intrastriatal 6-OHDA to 45 rats weighing 270-330 gr, in three different groups. We applied dissolver on control group; in other two groups we administered agomelatin at daily doses of 5 mg/kg and 20 mg/kg, respectively, for 15 days. At the end of this treatment process, motor coordination and skills were tested with sticky band test, open-field test and cylinder test, whereas, the severity of dopaminergic damage was tested with apomorphine induced rotation test. Results: in our study, we found out that in both doses of agomelatin (5 mg/kg/day and 20 mg/kg/day respectively), prevented progression of experimental Parkinson disease induced with 6-OHDA in rats. Conclusion: Agomelatin protected striatal neurons from destructive effects in experimental Parkinson's Disease model.trinfo:eu-repo/semantics/openAccessAgomelatinMelatoninParkinson's DiseaseAntidepressantRatArticle93216222WOS:00050157890000810.5222/buchd.2019.81084